Northrop Grumman (NOC)

Total Liabilities

$33.81B

Quarterly · Period ending: · USD

NOC logo

NOC Total Liabilities

Latest reported$33.81B
NOC Quarterly Total Liabilities ($1.43B → $33.81B)
High-resolution chart · PNG

NOC total liabilities history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Northrop Grumman Total Liabilities — Quarterly (USD)
Period endingTotal Liabilities (USD)
33,814,000,000
32,879,000,000
32,892,000,000
34,703,000,000
33,312,000,000
33,980,000,000
33,484,000,000
34,069,000,000
33,541,000,000
33,369,000,000
33,595,000,000
31,749,000,000
28,968,000,000
30,123,000,000
29,108,000,000
28,443,000,000
28,790,000,000
28,263,000,000
28,616,000,000
29,653,000,000
30,929,000,000
30,970,000,000
30,898,000,000
33,890,000,000
34,305,000,000
33,763,000,000
34,141,000,000
32,270,000,000
30,822,000,000
30,370,000,000
31,012,000,000
29,466,000,000
28,840,000,000
29,151,000,000
27,115,000,000
27,869,000,000
20,020,000,000
19,894,000,000
19,855,000,000
20,355,000,000
18,333,000,000
18,400,000,000
18,312,000,000
18,932,000,000
18,269,000,000
18,381,000,000
18,518,000,000
19,337,000,000
15,150,000,000
15,083,000,000
14,966,000,000
15,761,000,000
18,049,000,000
17,950,000,000
16,445,000,000
17,029,000,000
14,315,000,000
14,511,000,000
14,512,000,000
15,075,000,000
13,149,000,000
13,228,000,000
14,113,000,000
17,864,000,000
16,982,000,000
16,791,000,000
17,122,000,000
17,565,000,000
18,416,000,000
17,959,000,000
18,085,000,000
18,277,000,000
15,691,000,000
15,604,000,000
15,774,000,000
15,686,000,000
15,458,000,000
15,248,000,000
15,701,000,000
15,394,000,000
16,725,000,000
16,630,000,000
16,898,000,000
17,386,000,000
16,902,000,000
16,588,000,000
16,523,000,000
16,661,000,000
17,461,000,000
17,303,000,000
17,468,000,000
17,211,000,000
18,871,000,000
19,293,000,000
19,701,000,000
27,805,000,000
13,287,000,000
13,345,000,000
13,587,000,000
13,373,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.